These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16871462)

  • 21. Capsaicin receptor antagonists: a promising new addition to the pain clinic.
    Lambert DG
    Br J Anaesth; 2009 Feb; 102(2):153-5. PubMed ID: 19151045
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recent advances in the structure-activity relationship study of small-molecule sodium channel blockers with analgesic effects].
    Li W; Zhou Y; Liu HM; You QD
    Yao Xue Xue Bao; 2009 Feb; 44(2):101-8. PubMed ID: 19408676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analgesic effect of a polypeptide inhibitor of the TRPV1 receptor in noxious heat pain models.
    Andreev YA; Kozlov SA; Kozlovskaya EP; Grishin EV
    Dokl Biochem Biophys; 2009; 424():46-8. PubMed ID: 19341107
    [No Abstract]   [Full Text] [Related]  

  • 24. [The cannabinoid system and pain: towards new drugs?].
    Beltramo M
    J Soc Biol; 2009; 203(1):99-106. PubMed ID: 19358815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroscience: a local route to pain relief.
    McCleskey EW
    Nature; 2007 Oct; 449(7162):545-6. PubMed ID: 17914381
    [No Abstract]   [Full Text] [Related]  

  • 26. No gain, no pain: NaV1.7 as an analgesic target.
    King GF; Vetter I
    ACS Chem Neurosci; 2014 Sep; 5(9):749-51. PubMed ID: 25111714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    Haller VL; Cichewicz DL; Welch SP
    Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHI's Eighth Annual World Pharmaceutical Congress. Targeting pain with novel therapeutics: Part 1.
    Foster K
    IDrugs; 2009 Aug; 12(8):478-81. PubMed ID: 19629879
    [No Abstract]   [Full Text] [Related]  

  • 29. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
    Eibl JK; Strasser BC; Ross GM
    Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
    Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
    J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials in cancer - SMi's Seventh Annual Conference.
    Fakorede A
    IDrugs; 2008 Sep; 11(9):627-9. PubMed ID: 18763208
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceutical Portfolio & Product Life Cycle Management--SMi's fourth annual conference. 29-30 June 2009, London, UK.
    Beecher N
    IDrugs; 2009 Sep; 12(9):558-60. PubMed ID: 19697274
    [No Abstract]   [Full Text] [Related]  

  • 34. Activation of the transient receptor potential vanilloid-1 (TRPV1) channel opens the gate for pain relief.
    Jancsó G; Dux M; Oszlács O; Sántha P
    Br J Pharmacol; 2008 Dec; 155(8):1139-41. PubMed ID: 18997813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imidazopyridines: a novel class of hNav1.7 channel blockers.
    London C; Hoyt SB; Parsons WH; Williams BS; Warren VA; Tschirret-Guth R; Smith MM; Priest BT; McGowan E; Martin WJ; Lyons KA; Li X; Karanam BV; Jochnowitz N; Garcia ML; Felix JP; Dean B; Abbadie C; Kaczorowski GJ; Duffy JL
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1696-701. PubMed ID: 18243692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive neurodegenerative disease and pain.
    Shah S; Tear S
    IDrugs; 2005 Dec; 8(12):957-9. PubMed ID: 16320119
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of sensory methods for detecting target engagement in clinical trials of new analgesics.
    Chizh BA; Sang CN
    Neurotherapeutics; 2009 Oct; 6(4):749-54. PubMed ID: 19789077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoform-selective voltage-gated Na(+) channel modulators as next-generation analgesics.
    England S; Rawson D
    Future Med Chem; 2010 May; 2(5):775-90. PubMed ID: 21426202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
    Gomtsyan A; Bayburt EK; Keddy R; Turner SC; Jinkerson TK; Didomenico S; Perner RJ; Koenig JR; Drizin I; McDonald HA; Surowy CS; Honore P; Mikusa J; Marsh KC; Wetter JM; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3894-9. PubMed ID: 17507218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trials in CNS--SMi's eighth annual conference.
    Kirk R
    IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.